Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PBO Clear all
Terminated Phase 3 Interventional

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

NCT05712694
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
ADI PEG20, Placebo
Drug · Other
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years to 99 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavior Therapy (CBT), Nonspecific Supportive Therapy (PBO)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
63
States / cities
Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 1 Interventional

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

NCT06087406
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
Imvotamab, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

NCT03532009
View directory record Official record
Conditions
Heart Failure
Interventions
Sodium Zirconium Cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
National City, California • Stanford, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

NCT00383890
View directory record Official record
Conditions
Awake Fiberoptic Intubation
Interventions
Dexmedetomidine HCL Injection, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery

NCT00460473
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
30
States / cities
Loma Linda, California • Los Angeles, California • Pasadena, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tilavonemab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
57 Years to 88 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Generalized Anxiety Disorder Adjunct Study

NCT00534599
View directory record Official record
Conditions
Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
Interventions
Placebo, quetiapine fumarate XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

NCT03971422
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

NCT01096979
View directory record Official record
Conditions
Subcutaneous Abdominal Adiposity
Interventions
LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Anaheim, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

NCT04405570
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO)
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Northridge, California • Oxnard, California • Yucaipa, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

PRO 140 by IV Administration in Adults With HIV-1 Infection

NCT00613379
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

NCT06373146
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Gardena, California • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 1 Interventional

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

NCT01352312
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Pentostatin, Ofatumumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 21, 2026, 5:10 AM EDT